Avicanna Inc. AVCNF, a leading biopharmaceutical company specializing in plant-derived cannabinoid-based products, has announced the issuance of U.S. Patent No. US 20230025693A1 by the United States Patent and Trademark Office (USPTO). This patent covers Avicanna's deep penetrating topical <a href="https://www.benzinga.com/topic/cannabinoids">cannabinoid</a> composition and methods for treating musculoskeletal inflammation and pain.



"We are very happy with the issuance of another USPTO patent, this time on transdermal topical technology that has been a significant part of our research &amp; development, R&amp;D and clinical efforts," <a href="https://www.globenewswire.com/en/news-release/2024/08/27/2936127/0/en/Avicanna-Announces-United-States-Patent-and-Trademark-Office-Issuance-of-Patent-on-Topical-Technology.html">stated</a> Aras Azadian, CEO of Avicanna. "This technology was created through years of development, including AI-guided prediction modeling, pre-clinical trials and real-world evidence, and is part of our RHO Phyto commercial portfolio. We look forward to the incorporation of our patented technologies as we move forward to further evolving our pipeline, particularly those that target musculoskeletal pain and inflammation."



<h3 class="wp-block-heading">A New Frontier In Pain Management</h3>



Traditional pain relief methods often come with significant side effects, including those impacting the gastrointestinal, central nervous and cardiovascular systems. Avicanna's newly patented technology offers an alternative through a topical formulation that delivers active ingredients directly into deep tissue layers, potentially providing better efficacy with fewer side effects.



As the company stated, the significance of this technology was highlighted in a real-world evidence study where participants reported improvements in symptoms and quality of life related to musculoskeletal pain and inflammation. Seventy-one patients participated in the study, completing baseline testing and follow-up assessments after one month. The study evaluated the patient-reported efficacy of the RHO Phyto CBG Transdermal Gel, which contains 2% <a href="https://www.benzinga.com/topic/cbd">cannabidiol (CBD)</a> and 1% <a href="https://www.benzinga.com/topic/cbg">cannabigerol (CBG)</a>, across a range of conditions including arthritis, osteoarthritis, rheumatoid arthritis, fibromyalgia, and post-surgical pain.



<h3 class="wp-block-heading">About The Technology</h3>



The patented technology enhances the transdermal diffusion of cannabinoids through the epidermis and into sub-epidermal layers. This is accomplished by encapsulating cannabinoids within a nano- and micro-metric emulsion system with penetration enhancers, which are then stabilized in a gel matrix. The water-based gel leverages Avicanna's proprietary deep tissue technology, combining cannabinoids with synergistic terpenes and natural excipients to maximize therapeutic outcomes.



Cover image made with AI

Cannabis

Government

News

Psychedelics

Press Releases

Avicanna secures a U.S. patent for its innovative deep penetrating topical cannabinoid composition for treating pain and inflammation.

Avicanna Secures US Patent For Topical Cannabinoid Technology To Treat Pain And Inflammation - Avicanna (OTC:AVCNF)

Juan Spínelli

Avicanna

Aras Azadian

cannabidiol

cannabigerol

Cannabis Patents

USPTO

AVCNF

Avicanna Secures US Patent For Topical Cannabinoid Technology To Treat Pain And Inflammation

Avicanna Inc

Equities

Broad U.S. Equity ETFs

Technicals

Opinion

Signals

Pre-Market Outlook

Markets

Trading Ideas

The key market-moving data to watch today will be the February JOLTS report, covering Job Openings, Quits Levels, Quits Rate, and Layoffs Rate.

How To Trade SPY As Market Awaits JOLTS Data

Discover Financial Services

Stock Of The Day: Is The Move Higher In Discover Over?

Usa,Passport,With,Drivers,License,And,Social,Security,Card.

Personal Finance

Social Security Administration Relaxes ID Verification Rules After Backlash From Lawmakers And Advocates

handshake merger

Movers

General

MDALF

SatixFy Communications Ltd. Ordinary Share

SATX

SatixFy Communications shares surged after MDA Space unveiled a $193 million all-cash acquisition. The deal, offering $2.10 per share, enhances MDA&#39;s satellite communications technology with SatixFy&#39;s patented innovations.

MDA Space Expands Satellite Power With SatixFy Acquisition: Details

movers image

Sector ETFs

ETFs

XLRE

Leading And Lagging Sectors For April 1, 2025

Criticizes Elon Musk

Tech

LCID

TSLA

In the face of escalating protests and boycotts, Errol Musk, father of Elon Musk, has come forward to defend his son&#39;s cost-cutting initiatives for the U.S. government.

Elon Musk&#39;s Father Defends Tesla, Says Son Is &#39;Doing The Right Thing&#39; And The Stock Would Recover To $600 By 2025 End: Here&#39;s What Analysts Think About TSLA

Application error: a client-side exception has occurred (see the browser console for more information).